Clinical trials: Offspring, Adult
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Agitation in Adolescents and Young Adults With ASD
INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD
This is a Phase 2a, proof-of concept, 2-way, 2-period crossover, double-blind study to evaluate the safety and efficacy of INP105 as an acute treatment versus placebo in adolescents and young adults with autism spectrum disorder…
- Trial name
- CALM 201 (NCT05163717)
- Testing
- INP105
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Impel Pharmaceuticals
Recurrent High-grade Glioma
AsiDNA Children, Adolescents and Young Adults
HGG comprises diffuse midline gliomas (DMG), including diffuse infiltrating brainstem glioma (DIPG), characterised by histone gene mutations, as well as non-DM HGGs mainly in non-midline supratentorial areas, with distinct…
- Trial name
- AsiDNA (NCT05394558)
- Testing
- AsiDNA
- Where
- 10 sites in France
- Volunteers
- 8 people
- Sponsor
- Institut Curie
Sclerotic Graft Versus Host Disease, Imatinib Mesylate
Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Background: Chronic graft-versus-host disease (GVHD) is a common complication of stem cell transplant, resulting from the donor's immune cells attacking the cells of the body of the recipient.
- Trial name
- NCT00702689
- Testing
- Gleevec, STI571(Imatinib Mesylate)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Infections, Sepsis
A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and…
- Conditions
- Infections, Sepsis, SIRS
- Trial name
- NCT05142813
- Testing
- Diagnostic Test: Blood specimen collection
- Volunteers
- 1,100 people
- Sponsor
- mProbe Inc.
High Risk Acute Lymphoblastic Leukemia
HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL
The overall objective of this pilot study is to determine the safety and feasibility of a hybrid closed-loop insulin delivery system for children and young adults with high risk acute lymphoblastic leukemia, during the induction…
- Trial name
- NCT05006040
- Testing
- Hybrid Closed Loop System
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Nutrition Poor, Health Behavior
Virtual Technical Assistance for Child and Adult Care Food Program in Family Child Care Home
This study evaluates the effect of a fully virtual nutrition technical assistance training program for family child care home providers on the food they serve young children in their care and the food environment in their home.
- Trial name
- NCT04345874
- Testing
- Nutrition technical assistance, Children's environmental health technical assistance
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes.
- Trial name
- NCT07228117
- Testing
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 389 people
- Sponsor
- Medtronic MiniMed, Inc.
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Background: Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.
- Conditions
- Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
- Trial name
- NCT02390752
- Testing
- TURALIO(R)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Autistic Disorder
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients.
- Trial name
- NCT01474278
- Testing
- RO5028442
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
B-All, Acute Lymphoblastic Leukemia
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL.
- Trial name
- NCT05621291
- Testing
- NGS testing
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Dravet Syndrome (DS)
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS.
- Trial name
- NCT04940624
- Testing
- Soticlestat
- Where
- 66 sites in United States, Australia and 16 more
- Volunteers
- 144 people
- Sponsor
- Takeda
Sickle Cell Disease
Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.
Sickle cell disease is a genetic disease responsible for an abnormal hemoglobin.The anomaly has several consequences: a low hemoglobin rate (chronic anemia), plugs formed by red blood cells in blood vessels (extremely painful…
- Trial name
- NCT02608580
- Testing
- Survey
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Brugmann University Hospital
Loudness Hyperacusis, Autism Spectrum Disorder (ASD)
Transitional Intervention for Hyperacusis in Autism
The main goal of this clinical trial is to evaluate the effectiveness, benefits, and post-treatment persistence of an intervention for loudness hyperacusis in adults with autism spectrum disorder (ASD).
- Conditions
- Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
- Trial name
- TIHA (NCT07798297)
- Testing
- Transitional Intervention for Hyperacusis in Autism
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Central Florida
Low-Grade Glioma, Recurrent Low-Grade Glioma
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Trial name
- NCT04923126
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- St. Jude Children's Research Hospital
Diffuse Intrinsic Pontine Glioma
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Diagnosis of diffuse intrinsic pontine glioma (DIPG) for decades has relied on imaging studies and clinical findings. Histologic confirmation has been absent with surgical biopsy of brainstem tumors not believed to have…
- Trial name
- NCT01182350
- Testing
- Bevacizumab, Erlotinib, Temozolomide
- Where
- 23 sites in United States
- Volunteers
- 53 people
- Sponsor
- Karen D. Wright MD
HIV Disease
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
The purpose of this study was to compare the use of lamivudine (3TC) or emtricitabine (FTC) alone vs. continuing a failing highly active antiretroviral therapy (HAART) regimen in HIV infected children, adolescents and young…
- Trial name
- P1094 (NCT01338025)
- Testing
- HAART regimen, 3TC or FTC monotherapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 33 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Infections, Bacterial
Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function
This is a two-part study which will evaluate the PK, safety, and tolerability of a single 1500 milligram (mg) oral dose of gepotidacin in subjects with normal hepatic function and in subjects with mild, moderate, and severe…
- Trial name
- NCT03562117
- Testing
- Gepotidacin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo